ICO L'HOSPITALET HOSPITAL DURAN I REYNALS — Clinical Trial Site

18 Registered trials

9 Currently recruiting

Organisation

ICO L'HOSPITALET HOSPITAL DURAN I REYNALS

Location

Barcelona, Spain

Identifier

ORL-000006956

Address

Avinguda de la Granvia de l'hospitalet 199-203, 08908, Spain

Departments

Hematología
Hematology
ICO Hospitalet. Hospital Duran i Reynals
Internal Medicine
Medical Oncology
Medical Oncology Department
Neurology
Oncologia
Oncología Médica
Servicio de Hematología

Clinical trials at this site (18)

Search interface

A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has … Pending

2025-522288-13-00 Patients with pretreated extensive-stage small cell lun 4
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Su… Pending

2025-524255-32-00 Cutaneous squamous cell carcinoma (ccSCC) 4
Clinical trial to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab in patients with indolent clinical forms o… Recruiting

2024-511983-97-00 Adult patients with indolent MCL who have not previousl 4 2025-09-29
A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and be… Recruiting

2025-521459-22-00 Patients with resectable hepatocellular carcinoma (amen 4 2026-03-27
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 metastatic colorectal cancer 5 2025-07-21
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields), together with temozolo… Recruiting

2024-513550-30-00 Newly diagnosed Glioblastoma 5 2025-03-28
Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient… Recruiting

2024-515511-21-00 Neuroendocrine Carcinoma / G3 Neuroendocrine Tumours 4 2025-03-13
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Triple negative breast cancer 4 2024-11-04
A multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab i… Recruiting

2023-504647-14-00 Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic 4 2024-09-02
First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma Recruiting

2023-507213-97-00 Relapsed/refractory B-cell aggressive lymphoma 1 2024-05-09
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended

2024-518870-15-00 Multiple Myeloma 4 2022-10-03
A Study of the Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination with Venetoclax in AML Ended

2024-516294-78-00 Acute Myeloid Leukemia (AML) 4 2022-06-17
A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in com… Ended

2024-512575-12-00 ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS 9 2020-11-25
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM) Ended

2024-515032-76-00 mEtastatic Uveal Melanoma 9 2021-11-10
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma… Ended

2024-511316-25-00 Urothelial carcinoma (UC) 3 2019-06-04